The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for a new self-amplifying “replicon” mRNA “vaccine” to supposedly tackle the H5N1 influenza A virus (bird flu).
The fast track was awarded to Arcturus Therapeutics, a Bill Gates-funded company specializing in mRNA-based pharmaceuticals, for its ARCT-2304 mRNA “vaccine.”
One of Arcturus Therapeutics’ senior advisors, former CDC and FDA official Dr. Peter A. Patriarca, also advises the Gates Foundation.
As Slay News has previously reported, the “self-amplifying” or “replicon” mRNA shots contain the equipment needed to make more of itself once it enters cells.
The injections have been dubbed “replicon” vaccines because they are able to replicate inside the human body to produce more mRNA over time.
The new technology has provoked a worldwide backlash from experts and concerned citizens.
Despite concerns about the new injections, federal health officials are rushing the development of the new “replicon” injections.
The designation fast-tracks the development and review of the self-amplifying mRNA (sa-mRNA) vaccine platform.
ARCT-2304 is among the first of its kind aimed at “pandemic flu preparedness.”
The award is particularly notable given the current political environment.
Health and Human Services Secretary Robert F. Kennedy Jr. has promoted a more restrained approach to mass vaccination at the